Turpaz Industries (TRPZ) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
3 Nov, 2026Executive summary
Record Q2 sales of $46.8M, up 52.7% YoY, and H1 sales of $85.8M, up 39.4%; acquisitions and organic Taste and Scent growth offset Specialty Fine Ingredients weakness.
Combined growth strategy targets double-digit growth through organic expansion and synergistic acquisitions; management cited a strong global acquisition pipeline.
Financial highlights
Q2 gross profit was $18.1M, operating income $5.9M, net income $3.4M and adjusted EBITDA $9.9M, up 61.3%, 36.7% and 64.7% for reported growth metrics, respectively.
H1 gross profit was $32.5M, operating income $11.4M, net income $6.7M and adjusted EBITDA $18.3M; adjusted EBITDA grew 45.0%.
Adjusted EBITDA excludes $385K of Q2 and $691K of H1 non-recurring acquisition-related legal and other costs.
H1 operating cash flow was $11.3M, versus $0.2M in H1 2023; cash at June 30 was $18.7M.
Outlook and guidance
Strategy targets double-digit growth through organic expansion and acquisitions, leveraging cross-selling, procurement, R&D, marketing and regulatory synergies.
A European bank facility of up to €25M is intended mainly for acquisitions, growth, working capital and capital investment; it was undrawn at report publication.
Growth, acquisition integration and synergy realization are forward-looking and subject to execution risks and market changes.
Latest events from Turpaz Industries
- Record Q1 growth was led by Taste and acquisitions, while Specialty Fine Ingredients weakened.TRPZ
Q1 2024 - Acquisition-led growth lifted sales and adjusted EBITDA as Specialty Fine Ingredients weakened.TRPZ
Q3 2024 - FY24 sales rose 48.4%, with adjusted EBITDA up 54.8%.TRPZ
Q4 2024 - Record Q1 sales of $60.4M and adjusted EBITDA of $13.6M reflected organic growth and acquisitions.TRPZ
Q1 2025 - Q2 sales grew 35.6%, with 14.2% organic growth and a 23.1% adjusted EBITDA margin.TRPZ
Q2 2025 - Q3 sales rose 57.4% as organic growth and acquisitions lifted adjusted EBITDA 55.1%.TRPZ
Q3 2025 - Revenue rose 45.6% in 2025 as adjusted EBITDA margin reached 23.1%.TRPZ
Q4 2025 - Q1 revenue rose 38.6%; Phoenix and Romessence lifted the sales run rate to $380m.TRPZ
Q1 2026 - Acquisitions and organic growth drove record sales, while integration and production ramp-up shape the outlook.TRPZ
Q2 2026